Capsules (e.g., Of Gelatin, Of Chocolate, Etc.) Patents (Class 424/451)
  • Patent number: 11058661
    Abstract: In various embodiments, the present disclosure provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof having triglyceride levels of about 200 mg/dL to about 499 mg/dL, and hsCRP levels ?2.0 mg/L.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: July 13, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Sephy Philip
  • Patent number: 11046810
    Abstract: A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 29, 2021
    Assignee: PHARMATHEN S.A.
    Inventors: V. Theocharis Koftis, Efstratios Neokosmidis, Konstantina Karidi, Anastasia-Aikaterini Varvogli
  • Patent number: 11039637
    Abstract: A composition comprising probiotic bacteria, the composition comprising: (a) a core composition containing the probiotic bacteria and a stabilizer, wherein the total amount of probiotics in the mixture is from about 10% to about 90% by weight of the core composition; (b) an innermost coating layer, layered on said core composition, comprising at least one hydrophobic solid fat or fatty acid having a melting point lower than 60° C.; (c) an intermediate coating layer layered on said innermost coating layer, which when present in an aqueous solution in the amount of 0.1% weight/weight over the weight of the solution, has a surface tension lower than 60 mN/m, when measured at 25° C.; and (d) an outer coating layer, layered on said intermediate coating layer; wherein the composition is in the form of particles; food products containing the composition and methods of preparation thereof.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 22, 2021
    Assignee: DeGama Berrier Ltd.
    Inventor: Adel Penhasi
  • Patent number: 11033509
    Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: June 15, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
  • Patent number: 11033504
    Abstract: The invention relates to a film-forming composition comprising a fluidised hydroxypropyl starch and sorbitol, and to a film-coating method using said composition. The invention further relates to film-coated solid forms comprising a fluidised hydroxypropyl starch and sorbitol in the coating.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 15, 2021
    Assignee: ROQUETTE FRERES
    Inventors: Xavier Parissaux, Gregory Le Bihan, Sebastien Croquet
  • Patent number: 11026908
    Abstract: The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.
    Type: Grant
    Filed: July 16, 2017
    Date of Patent: June 8, 2021
    Assignee: MAPI PHARMA LTD.
    Inventors: Yoram Sela, Shai Rubnov
  • Patent number: 11013713
    Abstract: Embodiments of the invention relate generally to increasing adult height in individuals with no light perception (NLP).
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 25, 2021
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 10993915
    Abstract: The invention relates to self-assembling microparticles comprising a solid matrix and probiotic bacteria, wherein the solid matrix comprises soybean protein and a divalent or trivalent metal, and wherein the probiotic bacteria are distributed throughout the solid matrix; said matrix protects said probiotic bacteria during processing, storage, as well as during transit through the gastrointestinal tract, thus prolonging their lifetime and facilitating release into the intestine and improving their probiotic effect. The present invention also relates to the method for obtaining the self-assembling microparticles and to the products and compositions incorporating them.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 4, 2021
    Assignees: UNIVERSIDAD DE NAVARRA, CENTRO NACIONAL DE TECNOLOGIA Y SEGURIDAD ALIMENTARIA
    Inventors: Carolina González Ferrero, Carlos Javier González Navarro, Juan Manuel Irache Garreta, Beatriz Marín Calvo, Ana Romo Hualde, Raquel Virto Resano
  • Patent number: 10980828
    Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 20, 2021
    Assignee: L & F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10980265
    Abstract: Shown herein is a nutritional supplement containing apple cider vinegar (ACV), including compositions, formulations, and combinations of ingredients in the ACV nutritional supplement, as well as processes for manufacturing these supplements. The nutritional supplement can include ACV, a gelling agent such as pectin or gelatin, an oligosaccharide, a disaccharide, and water.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 20, 2021
    Assignee: Goli Nutrition Inc.
    Inventors: Michael Bitensky, Nicol Korner-Bitensky, Olivia Joan Dahm, Roger Arthur Tyre, Sharon Hoffman, Deepak Agarwal
  • Patent number: 10980266
    Abstract: Shown herein is a nutritional supplement containing apple cider vinegar (ACV), including compositions, formulations, and combinations of ingredients in the ACV nutritional supplement, as well as processes for manufacturing these supplements. The nutritional supplement can include ACV, a gelling agent such as pectin or gelatin, an oligosaccharide, a disaccharide, and water.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 20, 2021
    Assignee: Goli Nutrition Inc.
    Inventors: Michael Bitensky, Nicol Korner-Bitensky, Olivia Joan Dahm, Roger Arthur Tyre, Sharon Hoffman, Deepak Agarwal
  • Patent number: 10967021
    Abstract: The present invention provides a new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, or medication for its innocuity and its capacity to provide a diet enriched in anti-oxidants and anti-inflammatory compounds. Therefore, in accordance with the present invention is provided the use of athylakoid extract in the making of an oral composition for treating preventing a disease or disorder involving the formation of reactive oxygen species or inflammation. Also is provided a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orality administering an effective dose of a thylakoid extact.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: April 6, 2021
    Assignee: GROUPE SANTÉ DEVONIAN
    Inventors: Marc Purcell, Réjean Drouin
  • Patent number: 10966907
    Abstract: Provided is a die roll for manufacturing softgels, a softgel, and methods for producing a softgel. The die roll includes a die roll surface and a pocket defined therein. The pocket includes a floor, an interior sidewall surface, a chamfer, and an exterior sidewall surface. The floor is recessed relative to the die roll surface and the interior sidewall surface is connected to the floor and extends above the die roll surface to the chamfer. The pocket also includes a landing surface that is elevated from the die role surface and connects the chamfer to the exterior sidewall surface of the pocket. The landing surface includes a taper (such that the landing surface tapers inwardly towards the pocket floor) and a radius (such that the landing surface is not flat). Also provided is a softgel having a trailing edge thickness that is at least about 40% the thickness of the softgel wall thickness.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: April 6, 2021
    Assignee: BARLEAN'S ORGANIC OILS, LLC
    Inventor: John Puckett
  • Patent number: 10959957
    Abstract: The disclosed are shelf-stable beta-hydroxyisovaleric acid containing soft gel compositions and methods for making such compositions. In certain aspects, disclosed compositions comprise a plant-based capsule shell and a liquid formulation comprising beta-hydroxyisovaleric acid and at least one excipient, wherein the soft gel capsule is shelf-stable. In certain aspects, the excipient is selected from selected from choline salt, betaine, phosphatidylcholine, alpha-glycerophosphocholine, carnitine, adenosine 5?-triphosphate, or a combination thereof.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: March 30, 2021
    Assignee: TSI Group Ltd.
    Inventors: Martin Purpura, Ralf Jager, Jie Gu, Xiong Zheng, Iingwei Dai, Yaohua Zhang
  • Patent number: 10940118
    Abstract: The present disclosure provides methods and compositions related to nanoparticles comprising an encapsulated hydrophobic drug. The methods described herein provide nanoparticles having a small size and a narrow size distribution.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: March 9, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ying Liu, Zaijie Wang
  • Patent number: 10918595
    Abstract: A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Manabu Nakatani, Yohei Kawabata, Takeshi Sawada, Hiroshi Takasaki
  • Patent number: 10912783
    Abstract: Compositions and methods for the solubilization of steroid hormones are disclosed.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: February 9, 2021
    Assignee: THERAPEUTICSMD, INC.
    Inventors: Thorsteinn Thorsteinsson, Frederick D. Sancilio, Brian A. Bernick, Julia M. Amadio
  • Patent number: 10912758
    Abstract: A formulation comprising at least one ketogenic agent, at least one cannabinoid, at least one polyphenol, at least one phytonutrient, at least one dietary nutrient, at least one antioxidant, and at least one mineral, and mixtures and combinations thereof utilized for performance, cardiometabolic, cognitive, and women's health and wellness.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 9, 2021
    Inventors: Robert Firger, Gerald M. Haase
  • Patent number: 10898440
    Abstract: The present disclosure relates to aqueous composition comprising hydroxypropyl methyl cellulose acetate succinate (HPMCAS) polymer dispersed in water, wherein the dispersed polymer is partially neutralized with at least one alkaline material. The instant disclosure also relates to compositions for use in methods of making capsule shells endowed with bulk enteric properties. The present disclosure also relates to capsules made according with the compositions and methods of the present disclosure.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: January 26, 2021
    Assignee: Capsugel Belgium NV
    Inventors: Dominique Nicolas Cade, Hugues Straub
  • Patent number: 10898434
    Abstract: A new route is shown for at delivery in fighting drug resistant infections. Nanotubes and antibiotics and complexed non-covalently, with no chemical bonding, but through adsorption of antibiotics onto the nanotube surface governed by sufficiently strong molecular attraction between hydrophobic systems of the two. This allows the antibiotics to be freed from the nanotubes more easily as they reach the cell membrane. When antibiotics are introduced with nanotubes in this manner, bacterial resistance is mitigated by nanotube transport potentially into the membrane of the bacteria. Nanotubes used in this way help to overcome antibiotic resistance.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: January 26, 2021
    Assignee: Texas Christian University
    Inventor: Anton V. Naumov
  • Patent number: 10835881
    Abstract: A mixing device and methods of utilizing the same. More specifically, embodiments of the present disclosure relate to a mixing device that may be used to make medications and specialized pharmaceuticals for administration via intrathecal infusion therapy, or the like. A mixing device may comprise an upper chamber, a lower chamber having four compartments for accepting an amount of medication, wherein the upper chamber and the lower chamber may be coupled and may be used to mix and make medication accessible via a Luer Lock adapter, termination, or the like, wherein the device is in compliance with USP 797 standards.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: November 17, 2020
    Inventor: Roy C. Putrino
  • Patent number: 10828278
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: November 10, 2020
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Patent number: 10786458
    Abstract: Procedure for preparing enteric-coated pellets containing a proton pump inhibitor with benzimidazole structure, useful for preparing multi-particle pharmaceutical compositions for oral use that comprises the following stages: I) coat pure cellulose cores with a hydroalcoholic suspension that contains the proton pump inhibitor, a dibasic amino acid and polyvinylpyrrolidone; II) isolate the coated pure cellulose cores obtained in Stage I; III) apply an enteric coating to the particles obtained in Stage II above; and IV) dry the particles obtained in Stage III above and separate by size.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: September 29, 2020
    Assignees: Laboratorios Bago S.A., Eastbrand Holding GMBH
    Inventor: Mario Atilio Los
  • Patent number: 10786446
    Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: September 29, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
  • Patent number: 10780055
    Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: September 22, 2020
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Bernard Charles Sherman, Michael Spino
  • Patent number: 10751287
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 25, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Rama Abu Shmeis, Sheetal Muley, Zhixin Zong
  • Patent number: 10744096
    Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: August 18, 2020
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
  • Patent number: 10744137
    Abstract: A liquisolid tablet formulation, comprising a microcrystalline cellulose carrier; a silica coating; a crosslinked polyvinylpyrrolidone (PVP) superdisintegrant; a solvent comprising polyethylene glycol (PEG) 200 and caprylocaproyl macrogol-8 glycerides; tadalafil; and dapoxetine, wherein the liquid load factor of the formulation is 0.2-0.4 is provided. Methods of making the liquisolid tablet and methods of using the formulation for the treatment of male sexual dysfunction are also provided.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: August 18, 2020
    Assignee: King Abdulaziz University
    Inventors: Khalid M. El-Say, Fayez O. Alotaibi, Nabil A. Alhakamy, Abdelsattar M. Omar
  • Patent number: 10736916
    Abstract: A method for improving athletic or physical performance in a human includes administering to the human a composition or supplement formulation including a single administration of inorganic nitrate (NO3?), a single administration of inorganic nitrite (NO2?), or a combination thereof; and an additive. A method for increasing endurance in a human includes administering to the human a composition or supplement formulation including a single administration of inorganic nitrate (NO3?), a single administration of inorganic nitrite (NO2?), or a combination thereof; and an additive.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: August 11, 2020
    Assignee: THERMOLIFE INTERNATIONAL, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10729685
    Abstract: Orally administrable pharmaceutical compositions and methods of administration are provided. The pharmaceutical compositions provide abuse deterrent properties.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: August 4, 2020
    Assignee: OHEMO Life Sciences Inc.
    Inventors: Manish S. Shah, Ray J. DiFalco, Stefan Aigner
  • Patent number: 10716762
    Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: July 21, 2020
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Markus Krumme, Keith Jensen, Judith Dubach-Powell, Rudolf Hausmann
  • Patent number: 10709700
    Abstract: The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 14, 2020
    Assignee: Orphazyme A/S
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Gert Mads Bolwig, Carlos Roberto Camozzi
  • Patent number: 10695432
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: June 30, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10695431
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: June 30, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10688059
    Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: June 23, 2020
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Noreen Hassan
  • Patent number: 10675277
    Abstract: Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt or derivative thereof, together with complexation agents and pharmaceutically acceptable excipients; processes for the preparation thereof; and pharmaceutical compositions containing them. The complexes possess instantaneous redispersibility, increased apparent solubility and permeability compared to KALYDECO, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 9, 2020
    Assignee: NanGenex Nanotechnology Incorporated
    Inventors: Richárd Balázs Kárpáti, Gergo Patyi, Orsolya Basa-Dénes, Erzsébet Réka Angi, Tamás Jordán, Tamás Solymosi, Hristos Glavinas, Genovéva Filipcsei
  • Patent number: 10668431
    Abstract: A free standing liquid membrane is disclosed that can selectively separate objects based on the kinetic energy value of the objects such that either an object having a first kinetic energy value can pass through the free standing liquid membrane while retaining the membrane and/or an object having a second kinetic energy value is prevented from passing through the membrane while retaining the membrane. Advantageously, the free standing liquid membrane can remain intact for seconds to hours with multiple objects passing through the membrane.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: June 2, 2020
    Assignee: The Penn State Research Foundation
    Inventors: Tak-Sing Wong, Birgitt Boschitsch
  • Patent number: 10632094
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 28, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 10617608
    Abstract: The present invention relates to a composition for a hydrogel sheet including a cellulose ether, a gelling agent, and a gelling promoter, a hydrogel sheet prepared therefrom, and a method of preparing the hydrogel sheet. According to the present invention, the composition for a hydrogel sheet can be used to prepare a hydrogel sheet capable of maintaining the shape thereof without a support by limiting a type of the gelling agent and/or a viscosity of the cellulose ether included in the composition.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 14, 2020
    Assignee: LOTTE FINE CHEMICAL CO., LTD.
    Inventors: Ju Hee Shin, Ji Seon Jeong, Sung Hwan Bang, Ju Young Jung
  • Patent number: 10617666
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: April 14, 2020
    Inventors: Dania Birte Reiche, Silke Haag-Diergarten, Leah Jeanette Hennings, Saskia Kley, Anne M. Traas
  • Patent number: 10610528
    Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: April 7, 2020
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement, Angela Angusti, Cormac Long, Rodolphe Obeid, Laetitia Rodes, Billal Tir
  • Patent number: 10610541
    Abstract: A composition which comprises a prebiotic or a mixture thereof that, upon application to an individual's skin, has a beneficial effect on the skin and that is incorporated in the composition in the form of a multiplicity of tiny beads which comprise, in addition to the prebiotic, a matrix-forming agent, for example, mannitol and hydroxypropyl methylcellulose, and a filler, for example, microcrystalline cellulose, and a personal care composition which includes the beads.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 7, 2020
    Assignee: VANTAGE SPECIALTIES, INC.
    Inventor: Giorgio Dell'Acqua
  • Patent number: 10588932
    Abstract: The present invention relates to a use of a banana stamen extract for promoting hair growth. The banana stamen extract according to the present invention promotes gene expression of VEGF and IGF1 to enhance the proliferation level of hair follicles, so that the density of hairs grown is increased. In addition, the banana stamen extract also inhibits gene expression of SRD5A1, SRDA2 and AR to decrease hair loss, and promote the gene expression of KROX20 so as to significantly enhance hair growth.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: March 17, 2020
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Yu-Ting Lin
  • Patent number: 10576042
    Abstract: The present disclosure relates to a composition of at least one predominantly positively charged polyelectrolyte polymer and at least one predominantly negatively charged polyelectrolyte polymer, a preferred composition comprises poly-L-lysine and a gellan gum, preferably a methacrylate gellan gum. The present subject-matter further relates to methods for generating composition of the present disclosure and to uses of a mixture according to the disclosure for biomedical applications such as cellular and acellular systems for tissue engineering and regenerative medicine applications or as drug delivery systems, for the treatment of several diseases namely diabetes mellitus.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 3, 2020
    Assignee: ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING CELL BASED TECHNOLOGIES & THERAPIES ASSOCIAÇAO
    Inventors: Silvia Cristina Araújo Vieira, Joaquim Miguel Antunes De Oliveira, Rui Luís Gonçalves Dos Reis, Joana Catarina Da Silva Correia
  • Patent number: 10568893
    Abstract: Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 25, 2020
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Carl Genberg
  • Patent number: 10561631
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 18, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 10555902
    Abstract: The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 11, 2020
    Assignee: Handa Pharmaceuticals LLC
    Inventor: Fangyu Liu
  • Patent number: 10548892
    Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 4, 2020
    Assignee: NEUREN PHARMACEUTICALS LIMITED
    Inventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
  • Patent number: 10537551
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 21, 2020
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Patent number: 10525033
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 7, 2020
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox